Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Jun 25, 06:37 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Yesterday


News

Global Esophageal Cancer Market Report 2019: Merck's Keytruda Shows Utility in Subset of Esophageal Cancer

MRK

This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals. The report estimates that in 2017, there were 488,800 incident cases of esophageal cancer worldwide, and expects that number to increase to 534,700 incident cases by 2026. Photofrin, a two-step therapy that involves the injection of the photoactive drug followed by drug activation using laser therapy, is the only FDA-approved drug for esophageal cancer. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I-II, and only 9% in Phase III-IV.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, June 20


News

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

MRK

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries. NEW YORK (Reuters) - Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one way his administration would seek to lower drug costs to consumers could be through an international pricing index (IPI) that would determine what Medicare pays for certain medicines based on the prices set in a handful of other countries. Frazier, a lawyer by trade, did not say whether Merck would launch its own legal challenge to the proposed rule.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal

MRK

"This recognition reflects our commitment to building a culture where our talent can flourish and people can enjoy fulfilling careers – particularly in Boston , one of the most competitive biotechnology hubs in the world," said Chris Ross , country speaker for the U.S.-based business sectors of Merck KGaA, Darmstadt, Germany . This year's Best Places to Work companies were divided into five different categories: Extra small (20 to 49 employees), small (50 to 99 employees), medium (100 to 249 employees), large (250 to 999 employees) and extra-large (1,000 employees and over). All Merck KGaA, Darmstadt, Germany , news releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. The only exceptions are the United States and Canada , where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Here's Why I'm Sticking With Merck

MRK

About six months ago, I declared Merck & Co. The pharmaceutical sector has had its ups and downs this year, partly due to promises by President Trump and some members of Congress to fight for lower drug prices. Given this underperformance, are we sticking with Merck as our top choice for the year?

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development

MRK

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development. At a meeting with the investment community today, Merck (MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term. “Over the last five years, we have revitalized our focus on research in order to invent, develop and commercialize valuable and innovative medicines and vaccines that address many of the world’s most pressing health challenges.”. The company expects to continue its momentum and deliver strong revenue growth every year in the next five years, including 2023 – the year of greatest anticipated impact of the JANUVIA LOE – driven by demand for its portfolio of innovative products across oncology, vaccines, hospital acute care and animal health.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, June 19


News

AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer

MRK AZN +1 more MRK AZN AZN

Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said, “Advances in understanding the role of BRCA mutations and PARP inhibition have fundamentally changed how physicians can treat this aggressive type of cancer. In Japan, an estimated 10,672 new cases were expected to be diagnosed in 2018, with approximately 5,215 deaths. For all types of ovarian cancer, the five-year relative survival is approximately 47%. For newly-diagnosed advanced ovarian cancer, the primary aim of treatment is to delay progression of the disease for as long as possible. Pneumonitis: Occurred in <1% of patients exposed to LYNPARZA, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Most common adverse reactions (Grades 1-4) in ≥10% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for SOLO-1 were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection/influenza/ nasopharyngitis/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI (13%), thrombocytopenia (11%), and stomatitis (11%).

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Monday, June 17


News

Merck’s Inorganic Growth Strategy in 2019

MRK

On April 2, Merck & Co. issued a press release announcing the successful completion of its cash tender offer for Immune Design, with 86.75% of the target’s total outstanding common stock tendered on a fully diluted basis.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment
News

How Are Merck’s Revenues Trending in 2019?

MRK

On its first-quarter earnings conference call, Merck & Co. (MRK) guided for 2019 revenue of $43.9 billion–$45.1 billion, a YoY (year-over-year) rise of 4%–7% driven by its Oncology, Hospital and Specialty, Vaccines, and Animal Health segments.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, June 13


News

IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity

MRK WMT +1 more MRK WMT IBM

ARMONK, N.Y., NEW YORK, KENILWORTH, N.J., and BENTONVILLE, Ark., June 13, 2019 /PRNewswire/ -- IBM (NYSE: IBM), KPMG, Merck (MRK), and Walmart (WMT) today announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the United States. The proposed network is intended to help reduce the time needed to track and trace inventory; allow timely retrieval of reliable distribution information; increase accuracy of data shared among network members; and help determine the integrity of products in the distribution chain, including whether products are kept at the correct temperature. "We believe this is an ideal use for the technology because it can not only provide an audit trail that tracks drugs within the supply chain; it can track who has shared data and with whom, without revealing the data itself. Blockchain has the potential to transform how pharmaceutical data is controlled, managed, shared and acted upon throughout the lifetime history of a drug." IBM, KPMG, and Walmart, the largest retailer in the U.S., have extensive experience in implementing blockchain solutions to help enhance the safety and traceability of products.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Wednesday, June 12


News

Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

MRK

With the latest approval, Keytruda can be prescribed to previously untreated patients with metastatic or with unresectable, recurrent HNSCC as monotherapy in patients whose tumors express PD-L1 [CPS (combined proportion score )≥1) or in combination with chemotherapy regardless of PD-L1 expression. The sBLA was based on data from the phase III KEYNOTE-048 study, wherein Keytruda, as a monotherapy and in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, demonstrated significant improvement in overall survival compared to the standard of care in the given patient population. Keytruda generated sales of $2.27 billion in the first quarter of 2019, up around 5.6% sequentially and 55% year over year. In fact, the Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies, including more than 600 combination studies.

Read Full Details

Topics:
  • Business
  • Health
  • Entertainment